Tag Archive for: AC Immune

Weekly Roundup: Are you ready for Jefferies and London Life Sciences Week?🚨

Commit Biologics nominates first development candidate from BiCE™, its complement system engaging platform, and strengthens senior leadership Commit Biologics (“Commit”), the biotechnology company pioneering complement-powered immune engagers, announced the nomination of its first development candidate, COM002, as well as making two senior appointments, as it transitions from platform discovery to clinical development. COM002 will initially […]

AC Immune to Present at Jefferies Global Healthcare Conference 2026

Lausanne, Switzerland, November 11, 2026 — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharma company targeting the key pathologic misfolded proteins and pathways that drive neurodegenerative diseases, today announced that Martin ZĂĽgel, Interim CEO, will present and participate in a fireside chat at the annual Jefferies Global Healthcare Conference 2026, taking place November 16-19 in […]

Weekly Roundup: Perfect your pitch for BIO-Europe

Resolution Therapeutics announced positive interim Phase I/II EMERALD data for its Regenerative Macrophage Therapy RTX001 in end-stage liver disease Resolution Therapeutics, a clinical-stage biopharmaceutical company pioneering engineered Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, announced positive interim six-month data from its Phase I/II EMERALD trial evaluating RTX001, an investigational autologous engineered RMT, in […]

AC Immune Third Quarter 2026 Financial and Corporate Update

Positive clinical and regulatory progress achieved across wholly-owned pipeline ACI-7104 received FDA Fast Track designation, Investigational New Drug (IND) clearance, and reported positive Part 1 week-100 results from the Phase 2 VacSYn trial in Parkinson’s disease Positive interim safety and tolerability results from the Phase 1 trial of NLRP3 inhibitor ACI-19764 in healthy volunteers Lead […]

Weekly Roundup: One week till Optimum’s Annual Healthcare Investor Conference

Sofinnova Partners closed oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand […]

© Optimum Strategic Communications.